Dietary strontium (Sr) in a model of established osteopenic rats reduce the levels of 25hidroxyvitamin D

M GONZALES CHAVES; G PELLEGRINI; S FRIEDMAN; A PIGHIN; MC DE LANDETA; MAROTE C; ZENI SN

Montreal, Canada

Congreso; Therty Annual Meeting of the American Society for Bone and Mineral Research; 2008

ASBMR

Previously we found that vitamin D (vitD) status (i.e.normal or insufficient) interferes with bone mass recovery from bisphosphonate therapy in a model of OVX rats with established osteopenia (Bone 39: 837,2006). Using this model we investigated bone recovery from SrRanelate (SrRa) therapy. After 15 days post surgery and during 45 days, 20 OVX rats fed a diet containing 200IU% D (+D) and 20 a diet lacking vitD (-D) to obtain osteopenic/vitD repleted or depleted groups. Thereafter, 10 ?D and 10 +D OVX rats were treated with vehicle (-RaSr) or RaSr (900mg/kg/d) (+RaSr) for 45 days to obtain 4 subgroups (table). A SHAM group was run as control. At 0, 60 and 105 days total skeleton BMD and BMC(teBMC) were assessed by DXA, 25OHD by RIA (Diasorin) and serum Ca and phosphorus (P) by atomic absorption spectrophotometry (AAS) and colorimetric methods, respectively. At day 105, rats were sacrificed and tibia total bone volume (BV/TV) and Sr in bone were determined by histology and AAS, respectively. Results (mean±SE)